The May 2026 edition of IndiaTrialPulse by StriderDCT highlighted continued diversification in India’s multi-site clinical trial landscape, with Metabolic & Endocrinology emerging as the leading therapeutic area for the month.
Built on insights from the Clinical Trials Registry of India (CTRI), the report captured key shifts shaping India’s evolving clinical research environment.
Key Highlights
- 56 multi-site trials were registered during May
- Metabolic & Endocrinology emerged as the top therapeutic area, followed by Oncology and Women’s Health
- Global Pharma and Indian Pharma remained the dominant sponsor groups, contributing 18 and 17 trials, respectively
- 41 India-only studies significantly outnumbered the 15 global trials registered
- The West (113 sites), South (93 sites), and North (90 sites) led clinical site distribution, with Tier 1 cities (156 sites) ahead of Tier 2 (134 sites)
What The Numbers Indicate
- The rise of Metabolic & Endocrinology alongside sustained Oncology and Women’s Health activity points to evolving healthcare priorities and a more diversified clinical development pipeline in India.
- The continued dominance of India-only studies reflects strong confidence among domestic sponsors and a maturing local trial-execution ecosystem.
- While Tier 1 cities still lead site participation, the substantial Tier 2 presence (134 sites) signals ongoing geographic expansion beyond traditional metro hubs.
- IndiaTrialPulse continues to track the pulse of India’s clinical research ecosystem through structured monthly intelligence.
May 2026 may be remembered not for the volume of trials registered but for the signals it revealed, shifting disease priorities, growing regional participation, and a clinical research ecosystem steadily broadening its horizons.